Poltreg S.A. (WSE:PTG)

Poland flag Poland · Delayed Price · Currency is PLN
30.50
+1.00 (3.39%)
Aug 14, 2025, 10:02 AM CET
-42.23%
Market Cap 137.57M
Revenue (ttm) 250.00K
Net Income (ttm) -20.83M
Shares Out 4.66M
EPS (ttm) -4.46
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 16
Average Volume 3,218
Open 30.70
Previous Close 29.50
Day's Range 30.50 - 30.70
52-Week Range 28.50 - 56.80
Beta 0.91
RSI 38.28
Earnings Date Sep 3, 2025

About Poltreg

Poltreg S.A., a biotechnology company, researches and develops therapies for autoimmune diseases. It engages in the development of therapies for the treatment of type 1 diabetes in children, and multiple sclerosis. The company was incorporated in 2016 and is based in Gdansk, Poland. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2016
Employees 33
Stock Exchange Warsaw Stock Exchange
Ticker Symbol PTG
Full Company Profile

Financial Performance

In 2024, Poltreg's revenue was 350,000, a decrease of -74.98% compared to the previous year's 1.40 million. Losses were -18.71 million, 38.1% more than in 2023.

Financial Statements

News

There is no news available yet.